Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Passive immunity through IgG antibodies is a therapeutic approach that involves the transfer or administration of immunoglobulin G to provide immediate, short-term protection against infectious agents and their toxins. This process does not engage the recipient's own immune system to learn or remember the pathogen, but confers protection by directly neutralizing pathogens, promoting their clearance, or inactivating toxins. This form of immune protection is used both naturally (e.g., maternal IgG transfer across the placenta) and artificially (e.g., antibody therapies after pathogen exposure or for immunocompromised patients). While effective for rapid protection, it is not long-lasting, can be costly, and is associated with risks such as allergic reactions or, rarely, transmission of other agents.
Neutralization of pathogens (bacteria, viruses), Toxin neutralization, Opsonization to enhance phagocytosis
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin G antibody (IgG) (IgG).